Clinical Trial

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

Study acronym: BS-GLP
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-04; most recent amendment 2026-04-20.
Trial Details
NCT Number NCT07336862
Lead Sponsor China-Japan Friendship Hospital
Conditions Obesity
Enrollment 200 participants
Start Date 2024-01-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-23